AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

The biotech industry can be volatile even for relatively large companies. Amgen (NASDAQ: AMGN), one of the more prominent ...

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large ...